Skip to main content

Table 1 Major eligibility criteria

From: Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study

Inclusion
Men and women aged 50–80 years
End-stage renal failure and chronic haemodialysis for at least 3 months
Provision of written informed consent
Exclusion
Underlying haematological, neoplastic, GI, metabolic (other than diabetes) or infectious condition expected to reduce survival to less than 1 year
Patients likely to require a kidney transplant within 1 year
Statin therapy within the previous 6 months
History of serious reactions to statins
Unexplained CK >3 times ULN
Active liver disease (ALT >3 times ULN)
Uncontrolled hypothyroidism
A disallowed medication, such as another lipid-modifying agent or cyclosporin
  1. ALT: Alanine transaminase, CK: Creatine kinase, GI: Gastrointestinal, ULN: Upper limit of normal